title: Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy.
abstract: Squamous cell carcinoma of the lung accounts for 20-30% of non-small cell lung cancers (NSCLC). Despite the differences in disease characteristics between squamous and non-squamous NSCLC, both have historically been treated similarly in the clinic. Recently approved drugs have revealed differences in activity and safety profiles across histologic subtypes and have applicability in treating non-squamous, but not typically squamous, NSCLC. Exploration of immune checkpoints--co-inhibitory molecules used to regulate immune responses--has resulted in novel immunotherapies designed to interrupt signaling through the cytotoxic T lymphocyte-associated antigen-4 or programmed cell death protein-1 pathways on lymphocytes. Modulation of these pathways can lead to restored antitumor immune responses, and preliminary evidence shows that agents targeting these pathways have activity in lung cancer, including squamous NSCLC.
authors.affiliation: Multi-disciplinary Thoracic Oncology Program, University of North Carolina UNC Chapel Hill, Physicians Office Bldg. CB# 7305, 170 Manning Drive, 3rd Floor, Chapel Hill, NC, 27599-7305, USA, thomas_stinchcombe@med.unc.edu.
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Stinchcombe
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D011379:Prognosis
references.citation: Lung Cancer. 2010 Apr;68(1):105-10
references.pmid: 19545928
references.citation: J Clin Oncol. 2012 Jun 10;30(17):2046-54
references.pmid: 22547592
references.citation: Immunol Rev. 2009 May;229(1):12-26
references.pmid: 19426212
references.citation: Immunity. 1999 Aug;11(2):141-51
references.pmid: 10485649
references.citation: Blood. 2010 Aug 26;116(8):1291-8
references.pmid: 20472828
references.citation: Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11790-5
references.pmid: 12195015
references.citation: Lung. 2009 Nov-Dec;187(6):401-11
references.pmid: 19795170
references.citation: Science. 1996 Mar 22;271(5256):1734-6
references.pmid: 8596936
references.citation: Clin Dev Immunol. 2012;2012:656340
references.pmid: 22611421
references.citation: Immunity. 1995 Nov;3(5):541-7
references.pmid: 7584144
references.citation: N Engl J Med. 2012 Jun 28;366(26):2455-65
references.pmid: 22658128
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: Annu Rev Immunol. 2008;26:677-704
references.pmid: 18173375
references.citation: Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
references.pmid: 12218188
references.citation: Prostate. 2009 Nov 1;69(15):1694-703
references.pmid: 19670224
references.citation: Blood. 2009 Aug 20;114(8):1537-44
references.pmid: 19423728
references.citation: Am J Clin Oncol. 2015 Apr;38(2):220-6
references.pmid: 25806712
references.citation: Lancet Oncol. 2012 Oct;13(10):e418-26
references.pmid: 23026827
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: Int J Cancer. 2006 Jul 15;119(2):317-27
references.pmid: 16482562
references.citation: Mod Pathol. 2011 Oct;24(10):1348-59
references.pmid: 21623384
references.citation: J Exp Med. 2000 Oct 2;192(7):1027-34
references.pmid: 11015443
references.citation: Int J Oncol. 2006 May;28(5):1089-98
references.pmid: 16596224
references.citation: Nat Rev Immunol. 2004 May;4(5):336-47
references.pmid: 15122199
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2184-91
references.pmid: 15169807
references.citation: Science. 1995 Nov 10;270(5238):985-8
references.pmid: 7481803
references.citation: Nat Rev Immunol. 2008 Jun;8(6):467-77
references.pmid: 18500231
references.citation: Science. 2008 Oct 10;322(5899):271-5
references.pmid: 18845758
references.citation: Mod Pathol. 2012 Mar;25(3):405-15
references.pmid: 22056955
references.citation: Clin Cancer Res. 2011 Aug 15;17(16):5247-56
references.pmid: 21659461
references.citation: Clin Lung Cancer. 2013 Mar;14(2):157-63
references.pmid: 22868219
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1227-34
references.pmid: 19188680
references.citation: Immunity. 2007 Jul;27(1):111-22
references.pmid: 17629517
references.citation: Ann Surg. 2002 Dec;236(6):785-93; discussion 793
references.pmid: 12454517
references.citation: Mol Cell Biol. 2005 Nov;25(21):9543-53
references.pmid: 16227604
references.citation: Nat Med. 2002 Aug;8(8):793-800
references.pmid: 12091876
references.citation: Acta Cytol. 2006 Jul-Aug;50(4):423-9
references.pmid: 16901008
references.citation: N Engl J Med. 2013 Jul 11;369(2):122-33
references.pmid: 23724867
references.citation: Ann Oncol. 2013 May;24(5):1170-9
references.pmid: 23393121
references.citation: N Engl J Med. 2011 Jun 30;364(26):2517-26
references.pmid: 21639810
references.citation: Oncologist. 2009 Mar;14(3):253-63
references.pmid: 19221167
references.citation: Nat Rev Cancer. 2012 Mar 22;12(4):252-64
references.pmid: 22437870
references.citation: J Exp Med. 2009 Aug 3;206(8):1717-25
references.pmid: 19581407
references.citation: Nature. 2012 Sep 27;489(7417):519-25
references.pmid: 22960745
references.citation: Clin Cancer Res. 2013 Sep 15;19(18):4917-24
references.pmid: 23868869
references.citation: Br J Cancer. 2006 Jan 30;94(2):275-80
references.pmid: 16421594